Rankings
▼
Calendar
AMRX (Amneal Pharmaceuticals, Inc.) Stock Financials & Earnings | Market Cap Arena
AMRX
Amneal Pharmaceuticals, Inc.
Mkt Cap
$4B
Healthcare
·
Drug Manufacturers - Specialty & Generic
·
🇺🇸 United States
·
NASDAQ
Revenue (TTM)
$3.0B
Net Income (TTM)
$72M
EPS (TTM)
$0.22
Free Cash Flow (TTM)
$237M
Gross Margin
36.9%
Op. Margin
10.8%
Net Margin
2.4%
FCF Margin
7.8%
P/S Ratio (TTM)
1.4x
P/E Ratio (TTM)
58.9x
YoY Rev Growth
+8.0%
Employees
—
Earnings Reports
▶
Q4 2025
NEW
Browse All Reports
Quarterly
FY
Revenue & Profitability
Revenue
Gross Profit
Operating Income
Quarter
Revenue
Gross Profit
Op. Income
Q1 23
$558M
$178M
$34M
Q2 23
$599M
$220M
$80M
Q3 23
$620M
$233M
$76M
Q4 23
$617M
$225M
$14M
Q1 24
$659M
$238M
-$11M
Q2 24
$702M
$250M
$95M
Q3 24
$702M
$270M
$89M
Q4 24
$731M
$263M
$76M
Q1 25
$695M
$256M
$100M
Q2 25
$725M
$286M
$111M
Q3 25
$785M
$274M
-$117K
Q4 25
$814M
$297M
$115M
marketcaparena.com
Revenue Breakdown
AMRX
Amneal Pharmaceuticals, Inc.
Revenue Breakdown
Q4 2025
marketcaparena.com
Valuation
P/S Ratio
P/E Ratio
Quarter
P/S
P/E
Q1 23
1.9x
—
Q2 23
1.8x
—
Q3 23
1.8x
411.1x
Q4 23
1.8x
—
Q1 24
1.7x
—
Q2 24
1.6x
—
Q3 24
1.6x
—
Q4 24
1.5x
—
Q1 25
1.5x
—
Q2 25
1.5x
1257.5x
Q3 25
1.4x
719.4x
Q4 25
1.4x
58.9x
marketcaparena.com
Operating Cash Flow
Operating Cash Flow
Free Cash Flow
Quarter
Operating CF
Free CF
Q1 23
$140M
$128M
Q2 23
-$11M
-$24M
Q3 23
$81M
$68M
Q4 23
$136M
$104M
Q1 24
-$4M
-$24M
Q2 24
$40M
$29M
Q3 24
$142M
$121M
Q4 24
$118M
$95M
Q1 25
$7M
-$11M
Q2 25
$84M
$57M
Q3 25
$118M
$103M
Q4 25
$130M
$87M
marketcaparena.com
Capital Expenditures
CapEx
Quarter
CapEx
Q1 23
$12M
Q2 23
$12M
Q3 23
$13M
Q4 23
$32M
Q1 24
$20M
Q2 24
$11M
Q3 24
$21M
Q4 24
$23M
Q1 25
$18M
Q2 25
$27M
Q3 25
$15M
Q4 25
$43M
marketcaparena.com
OpEx vs Revenue Growth (YoY)
Revenue Growth
OpEx Growth
Quarter
Revenue Growth
OpEx Growth
Q1 23
+12.0%
+10.3%
Q2 23
+7.1%
-31.5%
Q3 23
+13.7%
+8.6%
Q4 23
+1.2%
+5.1%
Q1 24
+18.2%
+28.1%
Q2 24
+17.1%
+16.8%
Q3 24
+13.3%
+12.7%
Q4 24
+18.4%
+8.6%
Q1 25
+5.5%
-11.2%
Q2 25
+3.2%
+1.1%
Q3 25
+11.7%
+27.9%
Q4 25
+11.5%
+6.9%
marketcaparena.com
Stock-Based Compensation
SBC ($)
% of Revenue
Quarter
SBC ($)
% of Revenue
Q1 23
$8M
1.4%
Q2 23
$7M
1.1%
Q3 23
$7M
1.1%
Q4 23
$6M
1.0%
Q1 24
$7M
1.0%
Q2 24
$7M
1.0%
Q3 24
$7M
1.0%
Q4 24
$7M
1.0%
Q1 25
$7M
1.0%
Q2 25
$8M
1.1%
Q3 25
$8M
1.0%
Q4 25
$8M
1.0%
marketcaparena.com
OpEx Breakdown
R&D
G&A
S&M
SG&A
Quarter
R&D
G&A
S&M
SG&A
Q1 23
$40M
—
—
$102M
Q2 23
$39M
—
—
$106M
Q3 23
$42M
—
—
$113M
Q4 23
$47M
$97M
$12M
—
Q1 24
$39M
—
—
$113M
Q2 24
$37M
—
—
$116M
Q3 24
$61M
—
—
$119M
Q4 24
$56M
$94M
$34M
—
Q1 25
$42M
—
—
$118M
Q2 25
$50M
—
—
$124M
Q3 25
$63M
—
—
$138M
Q4 25
$35M
—
—
$146M
marketcaparena.com
Revenue Segments
Amneal Specialty Pharma Segment
Av K A R E Segment
Generics Segment
Quarter
Amneal Specialty Pharma Segment
Av K A R E Segment
Generics Segment
Q1 23
$92M
$122M
$344M
Q2 23
$97M
$128M
$374M
Q3 23
$97M
$132M
$391M
marketcaparena.com
War Chest
Cash & Equivalents
Short-Term Investments
Quarter
Cash
Short-term Investments
Total
Q1 23
$145M
$3M
$148M
Q2 23
$109M
$3M
$113M
Q3 23
$87M
$5M
$92M
Q4 23
$92M
$2M
$94M
Q1 24
$48M
$0
$48M
Q2 24
$44M
$3M
$47M
Q3 24
$74M
$0
$74M
Q4 24
$111M
$2M
$112M
Q1 25
$59M
$0
$59M
Q2 25
$81M
$0
$81M
Q3 25
$201M
$0
$201M
Q4 25
$311M
$0
$311M
marketcaparena.com
Shares Outstanding
Shares Outstanding
Quarter
Shares (Diluted)
QoQ Change
Q1 23
152M
+0.4%
Q2 23
155M
+1.8%
Q3 23
160M
+3.1%
Q4 23
244M
+52.6%
Q1 24
307M
+26.1%
Q2 24
319M
+3.8%
Q3 24
310M
-2.9%
Q4 24
310M
+0.1%
Q1 25
324M
+4.6%
Q2 25
322M
-0.5%
Q3 25
325M
+0.7%
Q4 25
325M
+0.0%
marketcaparena.com
Revenue Per Employee
Revenue / Employee
Year
Revenue/Employee
Employees
FY 14
—
—
FY 15
—
—
FY 16
—
—
FY 17
—
—
FY 18
$277K
6K
FY 19
$296K
6K
FY 20
$332K
6K
FY 21
$299K
7K
FY 22
$291K
8K
FY 23
$311K
8K
FY 24
$345K
8K
FY 25
$355K
9K
marketcaparena.com